23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation

Sepsis-3 Consensus Definitions & Pathophysiology

Sepsis is a medical emergency that accounts for more than one-third of all in-hospital deaths. Historically defined by the Systemic Inflammatory Response Syndrome (SIRS) criteria, modern critical care management adheres to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), which abandoned SIRS due to its poor specificity and lack of association with organ damage.

Modern Sepsis-3 Definitions

• Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection. Clinically, organ dysfunction is operationalized as an acute increase in total Sequential Organ Failure Assessment (SOFA) score of ≥2 points attributable to the infectious insult. A SOFA score increase of ≥2 points is associated with an in-hospital mortality rate exceeding 10%.
• Septic Shock: A lethal subset of sepsis in which underlying circulatory, cellular, and metabolic abnormalities are profound enough to substantially increase mortality. Septic shock is clinically identified by the persistence of both:
  1. Persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥65 mmHg; AND
  2. A serum lactate >2.0 mmol/L (18 mg/dL) despite adequate volume resuscitation.
  • This specific combination carries an in-hospital mortality rate exceeding 40%.

Pathophysiological Cascade

The pathophysiology of sepsis involves a complex interplay between pathogen-associated molecular patterns (PAMPs) and host pattern-recognition receptors (e.g., Toll-like receptors). This triggers an uncontrolled systemic release of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6), leading to:

1. Diffuse Endothelial Barrier Disruption: Loss of the endothelial glycocalyx and opening of inter-endothelial tight junctions, resulting in massive capillary leak, extravasation of albumin and intravascular water into the interstitial space, and severe hypovolemia.
2. Microvascular Thrombosis & Heterogeneity: Activation of tissue factor, downregulation of thrombomodulin and protein C, and impaired fibrinolysis produce widespread microvascular thrombi. Capillary beds display functional shunting, where unperfused capillaries sit adjacent to perfused ones, causing regional cellular hypoxia.
3. Mitochondrial Dysfunction (Cytopathic Hypoxia): Pro-inflammatory mediators and reactive nitrogen/oxygen species impair mitochondrial oxidative phosphorylation, leading to a state of cytopathic dysoxia where cells cannot utilize oxygen despite adequate macrovascular delivery. This stimulates anaerobic glycolysis and systemic hyperlactatemia.
4. Profound Peripheral Vasodilation: Overproduction of inducible nitric oxide synthase (iNOS) yields excessive nitric oxide (NO), causing vascular smooth muscle relaxation and refractory distributive shock.

---

The Sequential Organ Failure Assessment (SOFA) Score

The SOFA score evaluates acute dysfunction across six major organ systems on a graded 0 to 4 scale. A baseline score of zero is assumed in patients without preexisting chronic organ failure.

The Quick SOFA (qSOFA) Score

To facilitate bedside screening outside the intensive care unit, the Sepsis-3 task force introduced qSOFA. It incorporates three easily assessable clinical variables (1 point each):

1. Respiratory rate ≥22 breaths/min;
2. Altered mental status (Glasgow Coma Scale score <15);
3. Systolic blood pressure ≤100 mmHg.

Critical Clinical Distinction: A qSOFA score ≥2 indicates a high risk of prolonged ICU stay and in-hospital mortality. However, the Surviving Sepsis Campaign (SSC) 2021 guidelines specifically recommend against using qSOFA as a single screening tool for sepsis compared to SIRS, the National Early Warning Score (NEWS), or the Modified Early Warning Score (MEWS). This recommendation stems from extensive meta-analyses demonstrating that while qSOFA has high specificity (~96%), its sensitivity is unacceptably low (~50-60%), causing clinicians to miss or delay recognition of early sepsis.

---

Surviving Sepsis Campaign (SSC) 2021 1-Hour Bundle

The SSC guidelines emphasize rapid operational execution through the 1-Hour Resuscitation Bundle. Resuscitation must begin immediately upon recognition; all elements should ideally be initiated within the first hour of triage.

                    SSC 2021 1-HOUR BUNDLE OVERVIEW

  ┌─────────────────────────────────────────────────────────────────┐
  │ 1. MEASURE BLOOD LACTATE STAT                                   │
  │    • Re-measure within 2-4 hours if initial lactate >2.0 mmol/L │
  ├─────────────────────────────────────────────────────────────────┤
  │ 2. OBTAIN BLOOD CULTURES PRIOR TO ANTIMICROBIALS                │
  │    • Minimum 2 sets (aerobic + anaerobic)                       │
  │    • Do NOT delay antibiotics >45 minutes if access is delayed  │
  ├─────────────────────────────────────────────────────────────────┤
  │ 3. ADMINISTER BROAD-SPECTRUM IV ANTIMICROBIALS                  │
  │    • Within 1 hour for shock or definite sepsis                 │
  ├─────────────────────────────────────────────────────────────────┤
  │ 4. RAPID FLUID RESUSCITATION: 30 mL/kg BALANCED CRYSTALLOIDS    │
  │    • Within 3 hours for MAP <65, SBP <90, or Lactate >=4.0      │
  │    • Lactated Ringer's / Plasma-Lyte preferred over 0.9% Saline │
  ├─────────────────────────────────────────────────────────────────┤
  │ 5. APPLY VASOPRESSORS DURING OR AFTER RESUSCITATION             │
  │    • Maintain MAP >=65 mmHg (First-line: Norepinephrine)        │
  └─────────────────────────────────────────────────────────────────┘

Detailed Breakdown of Bundle Elements

1. Measure Blood Lactate Level

• Serum lactate serves as a surrogate marker of tissue hypoperfusion, anaerobic glycolysis, and adrenergic stimulation. Normal levels are <2.0 mmol/L.
• A lactate ≥4.0 mmol/L (36 mg/dL) mandates aggressive crystalloid resuscitation even if blood pressure appears normal (cryptic septic shock).
• Serial Lactate Monitoring: If the initial lactate is elevated (>2.0 mmol/L), re-measure within 2 to 4 hours. Resuscitation targeting a lactate clearance of ≥10% to 20% every 2 hours is associated with significant survival benefits.

2. Blood Cultures Prior to Antimicrobials

• Obtain at least two sets of blood cultures (each set consisting of one aerobic and one anaerobic bottle) via separate venipuncture sites.
• In patients with indwelling vascular catheters in place for >48 hours, draw at least one set percutaneously and one set through each lumen of the catheter to evaluate for catheter-related bloodstream infections (differential time to positivity >2 hours indicates line source).
• Crucial Rule: Do NOT delay antimicrobial therapy by more than 45 minutes if blood cultures cannot be promptly obtained.

3. Broad-Spectrum Empiric Antimicrobials

• Administer broad-spectrum empiric IV antimicrobials within 1 hour of recognition for patients presenting with septic shock or high probability of sepsis.
• For patients with possible sepsis without shock, conduct a rapid clinical evaluation within 3 hours: if infection remains likely, administer antimicrobials immediately.
• Regimens must cover common Gram-positive (including MRSA when risk factors are present) and Gram-negative organisms (including Pseudomonas aeruginosa in high-risk hosts), such as Vancomycin PLUS Piperacillin-tazobactam, Cefepime, or Meropenem.

4. Rapid Fluid Resuscitation: The 30 mL/kg Rule

• Administer an initial fixed volume of 30 mL/kg of IV crystalloid within the first 3 hours to patients presenting with:
  1. Septic shock (hypotension requiring vasopressors or SBP <90 mmHg / MAP <65 mmHg); OR
  2. Severe tissue hypoperfusion manifested by a serum lactate ≥4.0 mmol/L.
• Dosing Caveat: In patients with severe obesity (BMI ≥30 kg/m²), calculate the 30 mL/kg bolus based on ideal body weight (IBW) rather than total actual body weight to prevent iatrogenic fluid overload.

5. Early Vasopressor Application

• Initiate vasopressors during or immediately after fluid resuscitation if the patient remains hypotensive, targeting a MAP ≥65 mmHg.
• Do not withhold vasopressors until the full 30 mL/kg fluid bolus has finished if diastolic arterial pressure is critically low (e.g., DBP <40 mmHg) or MAP is <50 mmHg; early norepinephrine infusion restores coronary and systemic perfusion while fluids infuse.

---

Fluid Resuscitation: Balanced Crystalloids versus 0.9% Normal Saline

One of the most consequential paradigm shifts in modern critical care is the abandonment of 0.9% normal saline in favor of balanced crystalloids (e.g., Lactated Ringer's or Plasma-Lyte).

The Physiological Problem with 0.9% Normal Saline

• 0.9% Sodium Chloride is unphysiological: it contains 154 mEq/L of sodium and 154 mEq/L of chloride (osmolality 308 mOsm/L), with a Strong Ion Difference (SID) of zero.
• Rapid large-volume infusion of 0.9% saline produces hyperchloremic metabolic acidosis (normal plasma chloride is 98–106 mEq/L). The elevated chloride concentration displaces bicarbonate, causes renal afferent arteriolar vasoconstriction, reduces renal cortical blood flow, diminishes glomerular filtration rate, and promotes interstitial fluid extravasation.

The Balanced Crystalloid Solution

• Lactated Ringer's (LR): Contains 130 mEq/L Na, 109 mEq/L Cl, 4 mEq/L K, 2.7 mEq/L Ca, and 28 mEq/L lactate buffer (osmolality 273 mOsm/L, SID ~28 mEq/L).
• Plasma-Lyte A: Contains 140 mEq/L Na, 98 mEq/L Cl, 5 mEq/L K, 3 mEq/L Mg, 27 mEq/L acetate, and 23 mEq/L gluconate buffer (osmolality 294 mOsm/L, SID ~50 mEq/L).
• Myth Buster: The lactate buffer in Lactated Ringer's is sodium lactate, not lactic acid. In the liver, sodium lactate is metabolized into bicarbonate; it does not induce lactic acidosis or alter diagnostic serum lactate interpretations.

Landmark Trial Evidence

1. The SMART Trial (Semler et al., NEJM 2018; n=15,802 ICU patients): Demonstrated that the use of balanced crystalloids compared to saline significantly reduced the 30-day composite incidence of Major Adverse Kidney Events within 30 days (MAKE30)—defined as in-hospital death, new renal replacement therapy, or persistent renal dysfunction (14.3% vs. 15.4%, p=0.04). In the septic subgroup (n=1,641), 30-day mortality was significantly lower in the balanced crystalloid group (25.2% vs. 29.4%).
2. The SALT-ED Trial (Self et al., NEJM 2018; n=13,347 emergency department non-ICU patients): Demonstrated that balanced crystalloids significantly decreased MAKE30 compared to saline (4.7% vs. 5.6%, p=0.01).

Colloids and Albumin

• Hydroxyethyl Starches (HES): Strongly contraindicated in sepsis. Multiple large trials (6S, CHEST) proved that starch solutions increase mortality and the requirement for renal replacement therapy.
• Human Albumin: The SSC 2021 guidelines suggest using albumin (5% or 20%) as an adjunct in patients who have received large volumes of crystalloids (>30-40 mL/kg) and remain in shock. Albumin expands intravascular volume more efficiently than crystalloids and scavenges reactive oxygen species without worsening renal failure.

---

Vasopressor, Inotropic & Corticosteroid Pharmacology

                  VASOPRESSOR TITRATION HIERARCHY

  ┌─────────────────────────────────────────────────────────────┐
  │ FIRST-LINE: NOREPINEPHRINE                                  │
  │ • Dose: 0.02 - 1.0+ mcg/kg/min                              │
  │ • Alpha-1 (potent vasoconstriction) + Beta-1 (inotropic)   │
  │ • Target MAP >=65 mmHg; SOAP II: superior to dopamine       │
  └──────────────────────────────┬──────────────────────────────┘
                                 │ If requiring escalating doses
                                 ▼
  ┌─────────────────────────────────────────────────────────────┐
  │ SECOND-LINE: VASOPRESSIN (ARGIPRESSIN)                      │
  │ • Dose: FIXED non-titratable 0.03 units/min                 │
  │ • V1a receptor stimulation; restores endogenous deficiency  │
  │ • Spares adrenergic burden; do NOT titrate >0.03-0.04 U/min │
  └──────────────────────────────┬──────────────────────────────┘
                                 │ If MAP remains refractory
                                 ▼
  ┌─────────────────────────────────────────────────────────────┐
  │ THIRD-LINE: EPINEPHRINE                                     │
  │ • Dose: 0.01 - 0.5 mcg/kg/min                               │
  │ • Potent Alpha-1 + Beta-1/Beta-2; raises lactate (aerobic)  │
  └─────────────────────────────────────────────────────────────┘

  SPECIAL CIRCUMSTANCES:
  • Myocardial Dysfunction / Hypoperfusion: ADD DOBUTAMINE (2.5-20 mcg/kg/min)
  • Refractory Shock (Norepi >=0.25 mcg/kg/min): ADD IV HYDROCORTISONE 200 mg/d

1. Norepinephrine (First-Line)

• Receptor Affinity: Potent alpha-1 adrenergic agonist with modest beta-1 adrenergic activity and negligible beta-2 activity.
• Hemodynamics: Increases systemic vascular resistance (SVR) and arterial tone, elevating MAP. Its modest beta-1 effect preserves stroke volume and cardiac output without excessive tachycardia.
• The SOAP II Trial (De Backer et al., NEJM 2010; n=1,679): Compared norepinephrine to dopamine in shock. Dopamine was associated with a twofold increase in severe arrhythmogenic events (20.7% vs. 12.4%, p<0.001) and a significant increase in 28-day mortality among patients with cardiogenic shock. In septic shock, norepinephrine proved significantly safer. Dopamine is now strictly restricted to rare cases of shock associated with bradycardia and minimal arrhythmia risk.

2. Vasopressin (Second-Line Adjunct)

• Receptor Affinity: Stimulates vascular V1a receptors, activating phospholipase C and protein kinase C to induce calcium influx and smooth muscle contraction.
• Mechanism in Sepsis: Septic shock induces an initial surge followed by rapid depletion of endogenous neurohypophyseal vasopressin stores, coupled with impaired autonomic baroreflexes. Exogenous vasopressin restores vascular tone via a non-adrenergic pathway.
• Dosing Rule: Administered at a fixed, non-titratable dose of 0.03 units/min (some centers use 0.04 units/min) initiated when norepinephrine reaches moderate doses (typically 0.25 mcg/kg/min). Vasopressin reduces norepinephrine requirements and blunts adrenergic side effects (VASST trial, NEJM 2008). It must never be titrated like a catecholamine; doses >0.04 units/min induce intense coronary, mesenteric, and peripheral digital ischemia.

3. Epinephrine (Third-Line)

• Receptor Affinity: High-affinity agonist across alpha-1, beta-1, and beta-2 receptors.
• Role: Added to norepinephrine or used as salvage therapy when MAP remains refractory despite norepinephrine plus vasopressin.
• Board Pearl: Epinephrine infusion stimulates skeletal muscle beta-2 adrenergic receptors, upregulating the Na+/K+-ATPase pump and enhancing aerobic glycolysis. This routinely generates an increase in blood lactate levels within the first 6 to 12 hours, which represents a benign drug effect rather than worsening tissue hypoperfusion or treatment failure.

4. Dobutamine (Inotropic Support)

• Receptor Affinity: Potent beta-1 agonist with modest beta-2 and weak alpha-1 activity.
• Indication: Administered (2.5 to 20 mcg/kg/min) in patients exhibiting persistent hypoperfusion (elevated lactate, low ScvO2 <70%, poor capillary refill, oliguria) despite adequate fluid resuscitation and achieving MAP ≥65 mmHg, or in patients with echocardiographic evidence of myocardial dysfunction (elevated filling pressures and depressed cardiac output).

5. Stress-Dose Corticosteroids in Refractory Shock

• Indication: The SSC 2021 guidelines recommend intravenous corticosteroids only for patients with septic shock who require ongoing, escalating vasopressor therapy (e.g., norepinephrine or epinephrine dose ≥0.25 mcg/kg/min for at least 4 hours) despite adequate fluid resuscitation.
• Dosing: Hydrocortisone 200 mg/day IV, administered either as 50 mg IV every 6 hours or as a continuous IV infusion of 8.3 mg/hour (200 mg over 24 hours).
• Evidence Base: The APROCCHSS trial (Annane et al., NEJM 2018) demonstrated that hydrocortisone plus fludrocortisone significantly decreased 90-day all-cause mortality (43.0% vs. 49.1%, p=0.03) and increased vasopressor-free days in refractory septic shock. The ADRENAL trial (Venkatesh et al., NEJM 2018) showed faster shock resolution, reduced blood transfusion requirements, and shortened ICU length of stay.
• Diagnostic Testing: Random cortisol levels and ACTH stimulation tests are not recommended; therapy is initiated based solely on the clinical requirement for escalating vasopressors.

---

Assessment of Fluid Responsiveness & Hemodynamic Monitoring

While early fluid resuscitation is lifesaving, excessive fluid administration leads to interstitial edema, worsening gas exchange, intra-abdominal hypertension, prolonged mechanical ventilation, and increased mortality.

The Failure of Static Hemodynamic Measures

• Central Venous Pressure (CVP): CVP reflects right ventricular preload and thoracic compliance, not volume responsiveness. Systematic reviews show that CVP correlates poorly with changes in cardiac output (area under ROC curve ~0.56, equivalent to tossing a coin). The SSC guidelines strongly recommend against using CVP alone to guide fluid administration.

Dynamic Measures of Fluid Responsiveness

Dynamic parameters exploit respiratory-induced changes in intrathoracic pressure or reversible postural volume shifts to determine whether cardiac stroke volume will increase by ≥10% to 15% in response to fluid administration (the definition of a "fluid-responsive" patient).

                 DYNAMIC FLUID RESPONSIVENESS MEASURES

  1. PASSIVE LEG RAISE (PLR) TEST
     • Method: Shift from 45° semi-recumbent to flat with legs elevated 45°
     • Autotransfusion: Mobilizes ~300-500 mL venous blood from lower limbs
     • Evaluation: Requires REAL-TIME cardiac output / stroke volume monitor
     • Cutoff: Cardiac output increase >=10% confirms fluid responsiveness
     • Reversible: Hemodynamics return to baseline upon lowering legs

  2. PULSE PRESSURE VARIATION (PPV) & STROKE VOLUME VARIATION (SVV)
     • Mandatory Requirements: Fully sedated, mechanically ventilated (TV >=8 mL/kg),
       normal sinus rhythm, no spontaneous breathing efforts
     • Cutoff: PPV or SVV >12% - 13% indicates preload responsiveness

  3. POINT-OF-CARE ULTRASOUND (POCUS)
     • Inferior Vena Cava (IVC) Respiratory Collapsibility:
       - Spontaneously breathing: >50% inspiratory collapse (Caval Index) suggests hypovolemia
       - Mechanically ventilated: >15-18% inspiratory distensibility indicates responsiveness
     • Echocardiography: Assess Left Ventricular Outflow Tract Velocity-Time Integral (LVOT VTI)